文献速递前列腺癌

高危和极高危前列腺癌的根治性前列腺切除术或放疗:多学科前列腺癌门诊中适合任一治疗患者的经验

Radical prostatectomy or radiotherapy for high- and very high-risk prostate cancer: a multidisciplinary prostate cancer clinic experience of patients eligible for either treatment.
PubMed 文献 · BJU Int · 2019-05-29

本研究为前瞻性收集的回顾性研究,比较2004至2013年多学科前列腺癌门诊中适合任一治疗的高危和极高危前列腺癌患者接受根治性前列腺切除术(231例)与放疗联合雄激素剥夺治疗(73例)的结局。两组局部复发、远处转移失败和总生存均无显著差异;多学科门诊患者平均生存较匹配的SEER队列长16.9个月(95%CI 13.1-20.8)。

要点

  • 高危和极高危前列腺癌患者经多学科门诊评估后选择根治性前列腺切除术或放疗联合雄激素剥夺治疗,长期结局似乎相似。
  • 根治性前列腺切除术组与放疗联合雄激素剥夺治疗组局部复发、远处转移失败和总生存均无显著差异。
  • 多学科门诊患者平均生存较匹配的SEER队列长16.9个月(95%CI 13.1-20.8)。

核心结论

  • 在高危和极高危前列腺癌患者中,经多学科前列腺癌门诊咨询后认为适合根治性前列腺切除术或放疗联合雄激素剥夺治疗并接受治疗者,长期结局似乎相似。
  • 多学科前列腺癌门诊患者的结局优于匹配的SEER队列。

研究设计与样本

  • 前瞻性收集的回顾性研究,比较2004至2013年接受根治性前列腺切除术(231例)与放疗联合雄激素剥夺治疗(73例)的患者。
  • 按美国国家综合癌症网络风险分层计算各治疗组的生化复发、局部复发、远处转移失败和总生存。
  • 与SEER队列进行倾向性评分匹配比较总生存。

主要发现

  • 根治性前列腺切除术组与放疗联合雄激素剥夺治疗组局部复发无显著差异(HR 2.7,95%CI 1.0-7.9;P=0.06)。
  • 根治性前列腺切除术组与放疗联合雄激素剥夺治疗组远处转移失败无显著差异(HR 2.5,95%CI 0.8-7.8;P=0.1)。
  • 根治性前列腺切除术组与放疗联合雄激素剥夺治疗组总生存无显著差异(HR 1.35,95%CI 0.4-4.8;P=0.6)。
  • 多学科前列腺癌门诊患者平均生存较匹配的SEER队列长16.9个月(95%CI 13.1-20.8)。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare radical prostatectomy (RP) vs radiotherapy (RT) with androgen-deprivation therapy (ADT) in the setting of patients with high-risk and very high-risk (VHR) prostate cancer who were deemed eligible for either therapy and made a treatment choice after consultation in a multidisciplinary prostate cancer clinic (MDPCC), and to compare the MDPCC patients' outcomes to a matched Surveillance, Epidemiology and End Results (SEER) cohort. PATIENTS AND METHODS: Prospectively collected, retrospective study comparing patients who underwent RP (231 patients) vs RT+ADT (73) from 2004 to 2013. Biochemical recurrence (BCR), local recurrence, distant metastasis failure, and overall survival (OS) were calculated for each treatment group overall and according to National Comprehensive Cancer Network risk strata. A propensity score matched comparison with a SEER cohort was performed for OS. RESULTS: There was no difference in local recurrence (hazard ratio [HR] 2.7, 95% confidence interval [CI] 1.0-7.9; P = 0.06), distant metastasis failure (HR 2.5, 95% CI 0.8-7.8; P = 0.1) and OS (HR 1.35, 95% CI 0.4-4.8; P = 0.6) between patients undergoing RP vs RT+ADT. Patients treated via the MDPCC survived on average 16.9 months (95% CI 13.1-20.8) longer than those in the matched SEER cohort. CONCLUSIONS: Long-term outcomes appear similar amongst patients with high-risk and VHR prostate cancer deemed eligible for either RP or RT, and treated after consultation in a MDPCC. Outcomes of the MDPCC patients were superior to those of the matched SEER cohort.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Reichard CA, Hoffman KE, Tang C, et al. Radical prostatectomy or radiotherapy for high- and very high-risk prostate cancer: a multidisciplinary prostate cancer clinic experience of patients eligible for either treatment. BJU Int. 2019. PMID: 31009137. doi:10.1111/bju.14780

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。